ISO 18969 Clinical Evaluation: Key Changes to Know

Clinical evaluation remains one of the most critical and challenging elements of medical device compliance.

With the publication of ISO/DIS 18969, expected to become an effective international standard in the foreseeable future, manufacturers will soon have a globally harmonized framework for planning, conducting and documenting clinical evaluation activities.
This article summarizes what ISO 18969 is, why it matters, and how it will change the current approach to clinical evaluation once it enters into force (currently Draft International Standard, Stage: 40.20).

What is ISO/DIS 18969? 

ISO/DIS 18969, Clinical evaluation of medical devices, is a draft international standard that defines:

• A structured and repeatable clinical evaluation process.
• Terminology related to clinical evaluation.
• General principles for clinical evaluation.
• Roles and responsibilities of manufacturers and involved parties.

ISO/DIS 18969 applies to medical devices (excluding in vitro diagnostic devices, or IVDs) and covers the evaluation of clinical risks and benefits based on data derived from human use. This standard is intended to be applicable throughout the entire device lifecycle, including pre-market and post-market phases.

Why is ISO 18969 a game-changer

Today clinical evaluation is governed by a patchwork of guidance documents, regional regulations and best-practice interpretations, for example:

• MEDDEV 2.7/1 rev. 4 (EU legacy guidance).
• MDCG guidance documents under EU MDR.
• National or notified body expectations.

ISO 18969 aims to consolidate these principles into a single, internationally recognized standard, improving consistency, predictability and scientific rigor.
With the adaptation of ISO 18969 manufacturers will benefit of clearer expectations regarding clinical evidence and stronger alignment between clinical evaluation and risk management. They will also be more likely to get better support for global regulatory submissions and benefit of reduced ambiguity during audits and conformity assessment.

Clinical Evaluation: Now vs ISO 18969

One of the most valuable aspects of ISO 18969 is how it formalizes and standardizes practices that today are often interpreted differently.
Let’s compare the current clinical evaluation approach with the 18969 standard:

Core elements of ISO/DIS 18969 

Although still in draft form, ISO/DIS 18969 introduces several important concepts, such as:

• Standardized terminology, a shared vocabulary reduces misinterpretation between manufacturers, notified bodies and regulators.
• Lifecycle perspective, as clinical evaluation is not a one-time activity but a living process, supported by post-market clinical data and PMCF activities.
• Risk–benefit driven approach as clinical evaluation is linked to intended purpose, clinical claims, residuals risks and expected benefits.
• Defined evaluation process, including:
  • Real clinical data identification.
  • Critical appraisal of data quality and relevance.
  • Analysis of clinical risks and benefits.
  • Clear conclusions supporting safety and performance.

What will change for manufacturers

The future publication of ISO 18969 will require manufacturers to have:

1. Structured documentation:
   • Clearly document how clinical data were identified, selected and appraised,
   • Justify clinical claims using traceable evidence,
   • Demonstrate a transparent risk–benefit rationale.
2. Stronger scientific rigor, expect increased emphasis on:
   • Methodological quality of literature reviews,
   • Justification of equivalence claims,
   • Statistical and clinical relevance of data
3. Better integration accross systems, clinical evaluation will need to be:
   • Aligned with risk management (ISO 14971),
   • Consistent with post-market surveillance and PMCF outputs,
   • Integrated into the overall quality management system.

How to prepare – Anticipate the changes

Manufacturers can already take proactive steps by:

• Reviewing existing clinical evaluation procedures and identifying gaps against a structured, lifecycle-based approach.
• Strengthening the link between clinical evaluation and risk management files.
• Improving documentation of clinical evidence selection and appraisal criteria.
• Training regulatory and clinical teams on systematic clinical evaluation methodologies.

Early alignment will reduce future remediation efforts once the standard enters into force.

Final thoughts

ISO 18969:2026 is set to become a cornerstone standard for clinical evaluation of medical devices.
By introducing clarity, structure and global consistency, it will raise the bar for clinical evidence, but also provide manufacturers with a clearer path to compliance.

Organizations that start adapting their clinical evaluation strategy now will be better positioned for regulatory success in 2026 and beyond.

Contact us to discover more about Gap Analysis, Clinical Evaluation Revision and our Medical Device services!

Source: ISO/DIS 18969